4

Berberine HCl and Gliclazide in Experimental Diabetes: A Mechanistic and Therapeutic Comparison in Alloxan-Induced Diabetic Rats

AUTHORS DETAIL

Sammiya Iftikhar[1], Bilal Aslam[1*], Muhammad Haroon Muzaffar[2], Muhammad Umar Farooq[3], Bilal Javid[4], Baseer Ahmad[5*]

[1]Department of Pharmacy, Physiology and Pharmacology, The University of Agriculture, Faisalabad.

[2] Department of Animal Nutrition, The University of Veterinary and Animal Sciences, Lahore.

[3] Department of Livestock Production, Pir Mahr Ali Shah Arid Agriculture University, Rawalpindi

[4] National Institute for Genomics and Advanced Biotechnology, NARC, Islamabad.

[5]Faculty of Veterinary and Animal Sciences, Muhammad Nawaz Shareef University of Agriculture, Multan

*Corresponding author: cba933@gmail.com baseer.ahmad@mnsuam.edu.pk

Received: 4-Aug-2024 **Revised:** 23-Oct-2024 **Accepted:** 9-Nov-2024

Cite this Article as: Iftikhar S, Aslam B, Muzaffar MH, Farooq MU, Javid B and Ahmad B, 2024. Berberine HCl and Gliclazide in Experimental Diabetes: A Mechanistic and Therapeutic Comparison in Alloxan-Induced Diabetic Rats. In: Basit A, Khan SA, Muhyuddin S and Mughal MAS (eds), Anim Health Dis Management, Pioneer Page Publishers, Beijing, China, Vol. 2: 29-35. https://doi.org/10.5281/zenodo.15455550

Abstract

This chapter provides a comprehensive comparative analysis of Berberine HCl and gliclazide in the management of alloxan-induced diabetes, exploring their distinct mechanisms of action, therapeutic efficacy, and clinical applications. Berberine HCl, a natural isoquinoline alkaloid, demonstrates multimodal antidiabetic effects through AMPK activation, inhibition of hepatic gluconeogenesis, and enhancement of insulin sensitivity, coupled with significant antioxidant and anti-inflammatory properties. In contrast, gliclazide, a second-generation sulfonylurea, primarily stimulates insulin secretion via pancreatic KATP channel inhibition while offering additional benefits of endothelial protection and oxidative stress reduction. The discussion highlights how alloxan-induced beta-cell destruction creates a valuable model for evaluating these agents' differential efficacy, particularly in advanced diabetes scenarios. While gliclazide shows optimal effectiveness in early-stage diabetes with preserved beta-cell function, its utility declines with progressive beta-cell loss. Berberine HCl emerges as a promising alternative for late-stage diabetes due to its insulin-sensitizing and potential beta-cell regenerative properties that function independently of residual beta-cell capacity. Key findings from preclinical and clinical studies are critically examined, along with current limitations and future research directions. Special emphasis is placed on the need for clinical trials validating Berberine HCl's therapeutic potential, optimization of combination therapies, and investigation of its beta-cell regenerative capabilities. The chapter concludes by advocating for personalized diabetes treatment strategies that consider disease progression, metabolic profiles, and the complementary mechanisms of these two distinct therapeutic approaches. This analysis provides valuable insights for researchers and clinicians seeking to optimize pharmacological interventions for diabetes, particularly in cases of significant beta-cell dysfunction. The comparative framework underscores the importance of mechanism-based drug selection while highlighting promising avenues for future diabetes therapeutics development.

Keywords: Berberine HCl, Gliclazide, Alloxan-induced diabetes, Beta-cell dysfunction, Insulin sensitization

Introduction

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Globally, diabetes affects over 537 million adults, with projections estimating a rise to 783 million by 2045, underscoring its status as a leading public health crisis (International Diabetes Federation [IDF], 2021). Chronic hyperglycemia drives severe complications, including neuropathy, retinopathy, nephropathy, and cardiovascular diseases, necessitating lifelong management. While conventional therapies like insulin, metformin, and sulfonylureas remain

cornerstones of treatment, their limitations such as hypoglycemia risk, weight gain, and diminishing efficacy in advanced disease highlight the urgent need for novel therapeutic strategies.

Alloxan-induced diabetes in rodents has become a crucial experimental model for investigating beta-cell dysfunction and hyperglycemia. Alloxan, a beta-cytotoxic compound, specifically targets and destroys pancreatic insulin-producing beta-cells by inducing reactive oxygen species (ROS), thereby replicating the insulin-deficient hyperglycemia seen in type 1 diabetes (T1D) and late-stage type 2 diabetes (T2D) (Lenzen, 2008). This model offers a controlled environment to assess therapies aimed at beta-cell regeneration, insulin secretion, or improving insulin sensitivity. However, its applicability is somewhat limited by the acute destruction of beta-cells, which differs from the gradual autoimmune or metabolic beta-cell loss experienced by humans. Nevertheless, the alloxan model continues to be essential for exploring glucose dysregulation mechanisms and testing anti-diabetic drugs.

Evaluating natural compounds against synthetic drugs provides valuable insights into various therapeutic avenues. Berberine hydrochloride (Berberine HCl), a plant-derived bioactive alkaloid from sources like Berberis vulgaris, has gained attention for its multi-target anti-diabetic actions. It influences glucose metabolism through the activation of AMP-activated protein kinase (AMPK), suppression of hepatic gluconeogenesis, and improved insulin sensitivity, in addition to its antioxidant and anti-inflammatory effects (Yin et al., 2008). Conversely, gliclazide, a second-generation sulfonylurea, mainly promotes insulin secretion by closing ATP-sensitive potassium (KATP) channels in pancreatic beta-cells. It also has antioxidant properties that help reduce oxidative stress linked to diabetic complications (Drouin et al., 2001).

The rationale for comparing Berberine HCl and gliclazide lies in their divergent mechanisms of action and therapeutic implications. While gliclazide's efficacy depends on residual beta-cell function potentially limiting its utility in alloxan-induced models with severe beta-cell loss Berberine HCl's insulin-sensitising and extra-pancreatic effects may offer broader applicability in advanced diabetes. This chapter synthesizes preclinical evidence to evaluate their relative efficacy, mechanistic nuances, and potential synergies, providing a framework for optimizing diabetes management in contexts of beta-cell failure.

Alloxan-Induced Diabetes: Model Relevance and Limitations

The alloxan-induced diabetic rat model is a widely used experimental system for studying diabetes mellitus, particularly insulin-deficient hyperglycemia. Alloxan (2,4,5,6-tetraoxypyrimidine) exerts its diabetogenic effect through selective cytotoxicity toward pancreatic beta-cells, mimicking the pathophysiology of type 1 diabetes (T1D) and late-stage type 2 diabetes (T2D) characterized by significant beta-cell loss (Lenzen, 2008).

Mechanism of Alloxan Toxicity

Alloxan induces beta-cell destruction through a well-characterized mechanism involving the generation of reactive oxygen species (ROS). Upon administration, alloxan is rapidly taken up by beta-cells via the GLUT2 glucose transporter (Szkudelski, 2001). Inside the cell, it undergoes redox cycling, producing superoxide radicals and hydrogen peroxide, which cause oxidative damage to cellular DNA, proteins, and lipids. A critical target of alloxan toxicity is the inhibition of glucokinase, a key enzyme in glucose sensing and insulin secretion, further impairing beta-cell function (Lenzen & Panten, 1988). The resulting oxidative stress triggers apoptosis, leading to irreversible beta-cell necrosis and subsequent insulin deficiency.

Implications for Studying Insulin Deficiency and Therapeutic Interventions

The alloxan-induced diabetes model serves as a valuable tool for investigating insulin-dependent diabetes, as it replicates the severe beta-cell depletion characteristic of type 1 diabetes (T1D) and advanced type 2 diabetes (T2D) (Eleazu et al., 2013). This model is particularly useful for evaluating the therapeutic efficacy of different anti-diabetic agents, highlighting the limitations of insulin secretagogues like gliclazide in conditions of significant beta-cell loss, while demonstrating the potential advantages of insulin sensitizers such as Berberine HCl, which can improve glucose metabolism independently of beta-cell function (Zhang et al., 2010). Additionally, the model provides a platform for studying beta-cell regeneration, allowing researchers to assess whether experimental treatments can restore functional beta-cell mass (Ibrahim et al., 2016). Among its strengths, the alloxan model offers rapid induction of diabetes within 48–72 hours (Szkudelski, 2001), selective toxicity toward pancreatic beta-cells (Lenzen, 2008), and utility in studying oxidative stress mechanisms and potential cytoprotective therapies (Radenković et al., 2016). However, the model has notable limitations, including its acute induction of beta-cell necrosis, which contrasts with the gradual autoimmune destruction seen in human T1D (Lenzen, 2008), variability in response due to dose and species differences (Eleazu et al., 2013), and limited relevance to T2D, as it does not fully replicate the insulin resistance central to the disease (Szkudelski, 2001). These factors must be carefully considered when interpreting experimental results and translating findings to human diabetes.

Berberine HCl: A Natural Alkaloid with Anti-Diabetic Potential

Berberine hydrochloride (Berberine HCl) is a bioactive isoquinoline alkaloid primarily derived from medicinal plants such as Berberis vulgaris (barberry), Coptis chinensis (goldthread), and Hydrastis canadensis (goldenseal). Despite its poor oral bioavailability (~1% in humans) due to extensive first-pass metabolism and P-glycoprotein efflux (Liu et al., 2010), Berberine HCl exhibits significant therapeutic effects, partly attributed to its active metabolites (e.g., berberrubine and thalifendine) and its ability to accumulate in tissues such as the liver, pancreas, and adipose tissue (Tan et al., 2011).

The anti-diabetic mechanisms of Berberine HCl are multifaceted. It activates AMP-activated protein kinase (AMPK), a key regulator of cellular energy homeostasis, thereby enhancing glucose uptake in skeletal muscle and inhibiting hepatic gluconeogenesis (Yin et al., 2008). Additionally, Berberine HCl suppresses gluconeogenic enzymes such as glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), reducing excessive hepatic glucose output (Zhang et al., 2010). It also improves insulin sensitivity by upregulating insulin receptor expression and enhancing glucose transporter 4 (GLUT4) translocation in adipocytes and muscle cells (Lee et al., 2006). Beyond its metabolic effects, Berberine HCl exerts potent antioxidant and anti-inflammatory actions, scavenging reactive oxygen species (ROS) and inhibiting nuclear factor-kappa B (NF-κB) signaling, which mitigates diabetes-associated oxidative stress and tissue damage (Cicero & Baggioni, 2016).

Preclinical studies in diabetic rodents demonstrate Berberine HCl's efficacy in reducing fasting blood glucose, improving lipid profiles, and preserving pancreatic beta-cell function (Kong et al., 2004). Clinically, randomized controlled trials (RCTs) in type 2 diabetes patients report comparable hypoglycemic effects to metformin and sulfonylureas, with significant reductions in HbA1c (~1%–2%) and fasting glucose (~20%–30%) after 3 months of treatment (Yin et al., 2008; Zhang et al., 2010). Notably, Berberine HCl also improves lipid metabolism, lowering total cholesterol, LDL-C, and triglycerides, making it a promising adjunct therapy for metabolic syndrome (Affuso et al., 2012). Despite these benefits, its clinical use is occasionally limited by gastrointestinal side effects (e.g., constipation, abdominal discomfort), which are typically dose-dependent and reversible (Lan et al., 2015).

In summary, Berberine HCl's diverse mechanisms spanning AMPK activation, gluconeogenesis suppression, insulin sensitization, and antioxidant effects underscore its therapeutic potential in diabetes management. While preclinical and clinical evidence supports its efficacy, further large-scale, long-term studies are needed to optimize dosing strategies and evaluate its role in combination therapies.

Gliclazide: A Synthetic Sulfonylurea in Diabetes Management

Pharmacodynamics: KATP Channel Inhibition and Insulin Secretion

Gliclazide, a second-generation sulfonylurea, exerts its primary hypoglycemic effect by binding to sulfonylurea receptor 1 (SUR1) on pancreatic beta-cells, leading to the closure of ATP-sensitive potassium (KATP) channels (Ashcroft & Gribble, 1998). This depolarizes the beta-cell membrane, triggering voltage-gated calcium channel (VGCC) opening and subsequent calcium influx, which stimulates insulin exocytosis (Proks et al., 2002). Unlike first-generation sulfonylureas (e.g., glibenclamide), gliclazide demonstrates greater selectivity for pancreatic SUR1 over cardiac (SUR2A) or vascular (SUR2B) subtypes, reducing cardiovascular risks (Zhang et al., 2010). Its insulinotropic effect is glucose-dependent, meaning it enhances secretion predominantly in hyperglycemic states, thereby lowering hypoglycemia risk (Del Guerra et al., 2000).

Antioxidant and Endothelial Protective Effects Beyond insulin secretion, gliclazide exhibits unique pleiotropic properties:

Gliclazide demonstrates significant benefits beyond its primary insulinotropic effects, offering both antioxidant and endothelial protective properties that contribute to its therapeutic value in diabetes management. Its unique amino azabicyclo-octyl ring structure enables direct scavenging of reactive oxygen species (ROS), thereby inhibiting lipid peroxidation and protein glycation (Ozyazgan et al., 2005). Furthermore, gliclazide enhances cellular antioxidant defenses by upregulating enzymes such as glutathione peroxidase while reducing oxidative stress markers like malondialdehyde (MDA) in diabetic patients (Kajbaf et al., 2016). In addition to its antioxidant effects, gliclazide improves endothelial function by preserving nitric oxide (NO) bioavailability through the reduction of superoxide-mediated NO degradation, thereby promoting vasodilation (Matsumoto et al., 2004). It also exerts anti-inflammatory effects by suppressing pro-inflammatory cytokines (e.g., TNF-α, IL-6) and adhesion molecules (e.g., VCAM-1), which play key roles in endothelial dysfunction (Renier et al., 2003). These pleiotropic actions likely contribute to its favorable cardiovascular safety profile, as demonstrated in the ADVANCE trial, where gliclazide was associated with fewer microvascular complications compared to other sulfonylureas (Patel et al., 2008). Together, these properties position gliclazide as a multifaceted antidiabetic agent with benefits extending beyond glycemic control.

Clinical Applications and Limitations in Advanced Beta-Cell Dysfunction Clinical Use:

Gliclazide serves as a first-line therapy for type 2 diabetes (T2D) in patients with preserved beta-cell function, demonstrating efficacy in reducing HbA1c by 1.0-1.5% (Inzucchi et al., 2015). Its favorable safety profile, including lower hypoglycemia risk and renal excretion-independent metabolism, makes it particularly suitable for elderly patients (Leiter et al., 2018). The drug shows excellent potential in combination therapy, synergizing effectively with metformin or SGLT2 inhibitors to address both insulin resistance and secretion defects (Davies et al., 2018). However, its clinical utility diminishes significantly in advanced beta-cell dysfunction, such as late-stage T2D or alloxan-induced diabetes models, due to irreversible beta-cell loss (U.K. Prospective Diabetes Study Group, 1998). Additional limitations include moderate weight gain (approximately 1-4 kg) resulting from hyperinsulinemia's anabolic effects (Monami et al., 2013), and while the hypoglycemia risk is lower than first-generation sulfonylureas like glibenclamide, it remains a concern for patients with irregular meal patterns or renal impairment (Schopman et al., 2014). These factors necessitate careful patient selection and monitoring when implementing gliclazide therapy.

Gliclazide: A Synthetic Sulfonylurea in Diabetes Management

Gliclazide, a second-generation sulfonylurea, exerts its primary antidiabetic effect through selective inhibition of ATP-sensitive potassium (KATP) channels in pancreatic β-cells. This action triggers membrane depolarization, calcium influx, and subsequent insulin secretion, making it particularly effective in patients with preserved β-cell function (Ashcroft & Gribble, 2000). Unlike first-generation sulfonylureas, gliclazide demonstrates high specificity for the SUR1 receptor subtype predominant in pancreatic cells, contributing to its improved safety profile (Zhang et al., 2010). Beyond its insulinotropic effects, gliclazide possesses unique pleiotropic properties that enhance its therapeutic value. Its antioxidant capacity stems from the amino azabicyclo-octyl moiety, which directly scavenges reactive oxygen species and reduces oxidative stress markers like malondialdehyde (Ozyazgan et al., 2005). The drug also exhibits endothelial protective effects by improving nitric oxide bioavailability and reducing expression of pro-inflammatory cytokines and adhesion molecules (Matsumoto et al., 2004; Renier et al., 2003). These additional benefits may explain the reduced microvascular complications observed in the ADVANCE trial compared to other sulfonylureas (Patel et al., 2008).

Clinically, gliclazide serves as first-line therapy for type 2 diabetes, typically achieving HbA1c reductions of 1.0-1.5% (Inzucchi et al., 2015). Its favorable pharmacokinetic profile, including renal-independent metabolism and lower hypoglycemia risk, makes it particularly suitable for elderly patients (Leiter et al., 2018). The drug shows excellent synergy in combination regimens, particularly with metformin or SGLT-2 inhibitors, addressing both insulin secretion and resistance (Davies et al., 2018). However, its efficacy diminishes significantly in advanced diabetes with substantial β-cell loss, as demonstrated in both clinical studies and alloxan-induced diabetic models (UKPDS Group, 1998). Other limitations include modest weight gain (1-4 kg) due to hyperinsulinemia (Monami et al., 2013) and persistent (though reduced) hypoglycemia risk in patients with irregular meal patterns or renal impairment (Schopman et al., 2014). These characteristics necessitate careful patient selection, with gliclazide being most appropriate for early-stage type 2 diabetes patients with substantial residual β-cell function, while alternative therapies should be considered for those with advanced disease. The drug's unique combination of insulin secretagogue activity, antioxidant properties, and endothelial protection positions it as a valuable option in personalized diabetes management strategies.

Future Perspectives

The therapeutic potential of Berberine HCl in diabetes management could be further enhanced through strategic combination therapies, particularly for patients with advanced disease. Given its complementary mechanisms to conventional antidiabetics—such as metformin (AMPK activation), SGLT-2 inhibitors (renal glucose excretion), and GLP-1 receptor agonists (beta-cell preservation)—Berberine HCl may offer synergistic benefits in addressing both insulin resistance and beta-cell dysfunction. For instance, combining Berberine with gliclazide could mitigate the latter’s declining efficacy in late-stage diabetes by compensating for impaired insulin secretion through insulin-sensitizing effects. However, such combinations require rigorous evaluation for safety, pharmacokinetic interactions, and long-term outcomes.

A critical gap remains in translating preclinical evidence to clinical practice. While rodent studies consistently demonstrate Berberine’s efficacy in improving glycemic control, lipid metabolism, and beta-cell function, large-scale, randomized controlled trials (RCTs) in humans are limited. Future research should prioritize dose-optimization studies, standardized formulations (e.g., bioavailability-enhanced derivatives), and head-to-head comparisons with first-line drugs. Additionally, trials exploring Berberine’s effects on diabetes-related complications (e.g., neuropathy, nephropathy) would strengthen its therapeutic rationale.

Emerging evidence suggests Berberine may promote beta-cell regeneration—a groundbreaking prospect for diabetes reversal. Preclinical studies report its ability to upregulate pancreatic transcription factors (e.g., PDX-1) and stimulate neogenesis, though human data are lacking. Investigating these mechanisms, possibly through imaging techniques (e.g., PET scans for beta-cell mass quantification) or biomarker studies, could redefine its role in diabetes therapy. Furthermore, exploring Berberine's epigenetic modulatory effects (e.g., DNA methylation in beta-cells) may unveil novel pathways for therapeutic intervention.

Conclusion

This chapter has systematically evaluated the comparative efficacy of Berberine HCl and gliclazide in the context of alloxan-induced diabetic models, while exploring their distinct mechanisms of action, therapeutic benefits, and clinical limitations. Berberine HCl, a naturally derived alkaloid, demonstrates a multifaceted approach to diabetes management through AMPK activation, suppression of hepatic gluconeogenesis, and enhancement of insulin sensitivity, complemented by its antioxidant and anti-inflammatory properties. These pleiotropic effects make it particularly valuable in scenarios of advanced beta-cell dysfunction, where conventional insulin secretagogues like gliclazide may falter due to their dependence on residual beta-cell activity. Gliclazide, while effective in early-stage type 2 diabetes through its targeted action on pancreatic KATP channels, exhibits additional benefits such as endothelial protection and oxidative stress reduction, which contribute to its cardiovascular safety profile. However, its utility diminishes in late-stage diabetes characterized by significant beta-cell loss, highlighting the need for alternative or adjunct therapies. The preclinical evidence presented underscores Berberine HCl's potential not only as a glucose-lowering agent but also as a candidate for beta-cell regeneration, a feature that could revolutionize diabetes treatment if validated in human studies. Conversely, gliclazide remains a reliable option for patients with preserved beta-cell function, particularly when combined with other antidiabetic agents to address both insulin secretion and resistance.

Moving forward, the integration of these compounds into diabetes therapy demands a personalized approach, guided by the stage of disease, degree of beta-cell dysfunction, and individual metabolic profiles. Future research should prioritize large-scale clinical trials to validate the promising preclinical findings on Berberine HCl, optimize its bioavailability, and explore its synergistic potential with existing therapies. Similarly, further investigation into gliclazide's extra-pancreatic benefits could refine its use in specific patient subgroups. Together, these advancements hold the promise of more effective, tailored diabetes management strategies that address both hyperglycemia and its underlying pathophysiology. In summary, while both Berberine HCl and gliclazide offer distinct advantages, their optimal use hinges on a deeper understanding of their mechanisms, limitations, and potential synergies, an endeavor that will require continued collaboration between basic science and clinical research to translate these insights into tangible patient benefits.

References

1. Affuso, F., Mercurio, V., Fazio, V., & Fazio, S. (2012). Cardiovascular and metabolic effects of Berberine. World Journal of Cardiology, 4(4), 77–84. https://doi.org/10.4330/wjc.v4.i4.77
2. Ashcroft, F. M., & Gribble, F. M. (1998). Correlating structure and function in ATP-sensitive K+ channels. Trends in Neurosciences, 21(7), 288–294. https://doi.org/10.1016/S0166-2236(98)01225-9
3. Ashcroft, F. M., & Gribble, F. M. (2000). New windows on the mechanism of action of K(ATP) channel openers. Trends in Pharmacological Sciences, 21(11), 439-445. https://doi.org/10.1016/S0165-6147(00)01562-2
4. Cicero, A. F. G., & Baggioni, A. (2016). Berberine and its role in chronic disease. Advances in Experimental Medicine and Biology, 928, 27–45. https://doi.org/10.1007/978-3-319-41334-1_2
5. Davies, M. J., D'Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., ... & Buse, J. B. (2018). Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 41(12), 2669-2701. https://doi.org/10.2337/dci18-0033
6. Del Guerra, S., et al. (2000). Gliclazide preserves first-phase insulin secretion in pancreatic islets from type 2 diabetics. Diabetologia, 43(Suppl 1), A19.
7. Drouin, P., Standl, E., & Diamant, M. (2001). Gliclazide modified release: Results of a 2-year study in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 3(1), 31-39. https://doi.org/10.1046/j.1463-1326.2001.00102.x
8. Eleazu, C. O., Eleazu, K. C., Chukwuma, S., & Essien, U. N. (2013). Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans. Journal of Diabetes & Metabolic Disorders, 12(1), 60. https://doi.org/10.1186/2251-6581-12-60

9. Ibrahim, M. A., Al-Hizab, F. A., Abushouk, A. I., & Abdel-Daim, M. M. (2016). Nephroprotective effects of benzyl isothiocyanate and resveratrol against cisplatin-induced oxidative stress and inflammation. Frontiers in Pharmacology, 7, 280. https://doi.org/10.3389/fphar.2016.00280
10. International Diabetes Federation (IDF). (2021). IDF Diabetes Atlas, 10th edition. Brussels, Belgium: International Diabetes Federation. Retrieved from https://www.diabetesatlas.or
11. Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., ... & Matthews, D. R. (2015). Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Diabetes Care, 38(1), 140-149. https://doi.org/10.2337/dc14-2441
12. Kajbaf, F., et al. (2016). The antioxidant effects of gliclazide and metformin in type 2 diabetes. Diabetes & Metabolism, 42(2), 89–94. https://doi.org/10.1016/j.diabet.2015.07.003
13. Kong, W., Wei, J., Abidi, P., et al. (2004). Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nature Medicine, 10(12), 1344–1351. https://doi.org/10.1038/nm1135
14. Lan, J., Zhao, Y., Dong, F., et al. (2015). Meta-analysis of the effect and safety of Berberine in the treatment of type 2 diabetes mellitus. PLOS ONE, 10(8), e0136175. https://doi.org/10.1371/journal.pone.0136175
15. Lenzen, S., & Panten, U. (1988). Alloxan: History and mechanism of action. Diabetologia, 31(6), 337–342. https://doi.org/10.1007/BF02341500
16. Lenzen, S. (2008). The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia, 51(2), 216–226. https://doi.org/10.1007/s00125-007-0886-7
17. Lee, Y. S., Kim, W. S., Kim, K. H., et al. (2006). Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 55(8), 2256–2264. https://doi.org/10.2337/db06-0006
18. Liu, Y. T., Hao, H. P., Xie, H. G., et al. (2010). Extensive intestinal first-pass elimination and predominant hepatic distribution of Berberine explain its low plasma levels in rats. Drug Metabolism and Disposition, 38(10), 1779–1784. https://doi.org/10.1124/dmd.110.033936
19. Leiter, L. A., Yoon, K. H., Arias, P., Langslet, G., Xie, J., Balis, D. A., ... & Meininger, G. (2018). Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: A randomized, double-blind, phase 3 study. Diabetes Care, 41(3), 583-592. https://doi.org/10.2337/dc17-1522
20. Matsumoto, K., Yano, M., Miyake, S., Ueki, Y., Yamaguchi, Y., Akazawa, S., & Tominaga, Y. (2004). Effects of gliclazide on serum lipids and lipoprotein levels in patients with non-insulin-dependent diabetes mellitus. Metabolism, 43(4), 469-473. https://doi.org/10.1016/0026-0495(94)90078-7
21. Monami, M., Dicembrini, I., Kundisova, L., Zannoni, S., Nreu, B., & Mannucci, E. (2013). A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 16(9), 833-840. https://doi.org/10.1111/dom.12287
22. Matsumoto, K., et al. (2004). Gliclazide reduces monocyte adhesion to endothelial cells. Diabetes Research and Clinical Practice, 66(Suppl 1), S127–S131. https://doi.org/10.1016/j.diabres.2003.08.013
23. Ozyazgan, S., Kutluata, N., Afşar, S., Ozdemir, O., & Kanit, L. (2005). Effect of gliclazide on erythrocyte lipid peroxidation and antioxidant enzymes in dynamic exercise-conditioned type 2 diabetics. Acta Diabetologica, 42(4), 179-185. https://doi.org/10.1007/s00592-005-0198-7
24. Patel, A., et al. (2008). ADVANCE trial: Effects of gliclazide on microvascular outcomes. The Lancet, 371(9626), 1563–1574. https://doi.org/10.1016/S0140-6736(08)60642-8
25. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L., ... & ADVANCE Collaborative Group. (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 358(24), 2560-2572. https://doi.org/10.1056/NEJMoa0802987
26. Radenković, M., Stojanović, M., & Prostran, M. (2016). Experimental diabetes induced by alloxan and streptozotocin: The current state of the art. Journal of Pharmacological and Toxicological Methods, 78, 13–31. https://doi.org/10.1016/j.vascn.2015.11.00
27. Renier, G., Desfaits, A. C., & Serri, O. (2003). Gliclazide decreases low-density lipoprotein oxidation and monocyte adhesion to the endothelium. Metabolism, 52(6), 693-698. https://doi.org/10.1016/S0026-0495(03)00028-3
28. Renier, G., et al. (2003). Anti-inflammatory effects of gliclazide in human endothelial cells. Diabetes, 52(3), 810–817. https://doi.org/10.2337/diabetes.52.3.810

29. Schopman, J. E., Simon, A. C., Hoefnagel, S. J., Hoekstra, J. B., & Scholten, R. J. (2014). The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: A systematic review and meta-analysis. *Diabetes/Metabolism Research and Reviews, 30*(1), 11-22. https://doi.org/10.1002/dmrr.2470
30. Szkudelski, T. (2001). The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiological Research, 50(6), 537–546. PMID: 11829314
31. Tan, W., Li, Y., Chen, M., & Wang, Y. (2011). Berberine hydrochloride: Anticancer activity and nanoparticulate delivery system. International Journal of Nanomedicine, 6, 1773–1777. https://doi.org/10.2147/IJN.S22683
32. UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet, 352(9131), 837-853. https://doi.org/10.1016/S0140-6736(98)07019-6
33. U.K. Prospective Diabetes Study Group. (1998). Sulfonylurea failure in T2D. The Lancet, 352(9131), 837–853. https://doi.org/10.1016/S0140-6736(98)07019-6
34. Yin, J., Xing, H., & Ye, J. (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism, 57(5), 712-717. https://doi.org/10.1016/j.metabol.2008.01.013
35. Zhang, H., Wei, J., Xue, R., et al. (2010). Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism, 59(2), 285–292. https://doi.org/10.1016/j.metabol.2009.07.029
36. Zhang, C. L., Katoh, M., Shibasaki, T., Minami, K., Sunaga, Y., Takahashi, H., ... & Seino, S. (2010). The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science, 325(5940), 607-610. https://doi.org/10.1126/science.1172256.